Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

被引：0
|
作者：
Ciruelos, E. M. [1 ]
Hamilton, E. P. [2 ]
Kim, S-B. [3 ]
Im, Y-H. [4 ,5 ]
Solis, E. Segui [6 ]
Saenz, J. A. Garcia [7 ]
Di Sanzo, A. [8 ]
Lizarbe, M. Dominguez [9 ]
Wasserman, T. [10 ]
Theall, K. P. [11 ]
Ibrahim, N. K. [12 ]
机构：
[1] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Med Dept Hematol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Med Oncol Div, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[6] Hosp Clin August Pi Sunyer Biomed Res Inst IDIBAP, Dept Med Oncol, Barcelona, Spain
[7] Inst Invest Sanitaria Hosp Clinico San Carlos, Dept Med Oncol, Madrid, Spain
[8] Biostatist & Data Management Dept, Menarini Grp, Florence, Italy
[9] Menarini Grp, Clin Res Dept, Florence, Italy
[10] Global Med Affairs Dept, Menarini Grp, Florence, Italy
[11] Global Product Dev Dept, Menarini Grp, New York, NY USA
[12] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
364P
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [1] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study
    Ibrahim, Nuhad K.
    Hamilton, Erika P.
    Kim, Sung-Bae
    Im, Young-Hyuck
    Segui, Elia
    Garcia-Saenz, Jose A.
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Lizarbe, Manuel Dominguez
    Wasserman, Tomer
    Theall, Kathy Puyana
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Ibrahim, Nuhad
    Kim, Sung-Bae
    Lin, Nancy
    Awada, Ahmad
    Gil, Eva Ciruelos
    Tonini, Giulia
    Vallespir, Bartomeu Piza
    Theall, Kathy Puvana
    Hamilton, Erika
    CANCER RESEARCH, 2024, 84 (09)
  • [3] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Awada, Ahmad
    Lin, Nancy
    Zuefle, Sebastian
    Scartoni, Simona
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 30 - 31
  • [4] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Lin, Nancy U.
    Awada, Ahmad
    Gil, Eva Ciruelos
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    CANCER RESEARCH, 2024, 84 (07)
  • [5] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [6] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
    Rugo, Hope S.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Bardia, Aditya
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Kaklamani, Virginia G.
    Romero, Paula Munoz
    Vallespir, Bartomeu Piza
    Wasserman, Tomer
    Theall, Kathy Puyana
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Tolaney, Sara
    Kaklamani, Virginia
    Tonini, Giulia
    Matheny, Shannon
    Theall, Kathy Puvana
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [8] A Multicenter, Phase Ib/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
    Casasanta, Nicole
    Landry, Chrystal
    Shao, Theresa
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Berger, Natalie
    Moshier, Erin
    Joshi, Gargi Atul
    Vaccaro, Rita
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
    Jhaveri, Komal
    Lim, Elgene
    Jeselsohn, Rinath
    Ma, Cynthia
    Hamilton, Erika
    Osborne, Cynthia
    Bhave, Manali
    Kaufman, Peter
    Beck, J. Thaddeus
    Manso, Luis
    Parajuli, Ritesh
    Wang, Hwei-Chung
    Tao, Jessica
    Dhakal, Ajay
    Pierga, Jean-Yves
    Lu, Yen-Shen
    Larson, Tim
    Gilarranz, Yolanda Jerez
    Ismail-Khan, Roohi
    Bacchion, Francesca
    Karacsonyi, Claudia
    Li, Yujia
    Estrem, Shawn T.
    Nguyen, Bastien
    Beeram, Muralidhar
    CANCER RESEARCH, 2024, 84 (09)
  • [10] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope S.
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara A.
    Loibl, Sibylle
    Kummel, Sherko
    Scartoni, Simona
    Matheny, Shannon
    Theall, Kathy Puyana
    O'shaughnessy, Joyce
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
12345